# XL092 and Cemiplimab in BRAF WT Thyroid Cancer

> **NCT06902376** · PHASE1 · RECRUITING · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 12 (estimated)

## Conditions studied

- Anaplastic Thyroid Cancer
- Thyroid Cancer
- BRAF Mutation-Related Tumors

## Interventions

- **BIOLOGICAL:** Cemiplimab
- **DRUG:** XL092

## Key facts

- **NCT ID:** NCT06902376
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-03
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-08-31
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-11-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06902376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06902376, "XL092 and Cemiplimab in BRAF WT Thyroid Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06902376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*